{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:53Z","timestamp":1777934633322,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Elotuzumab in combination with dexamethasone and immunomodulating agents (IMiDs) lenalidomide or pomalidomide is 2nd to 4th line therapy for multiple myeloma. The labelled dosage of dexamethasone for use in conjunction with elotuzumab and IMiDs splits the dexamethasone dose into two administrations, one oral and one intravenous, on the days of each elotuzumab infusion. Administration of split dose dexamethasone on days of elotuzumab administration is based on the registration trials submitted for drug approval and was intended to ensure standard well-timed immunotherapy premedication using pharmacologically equivalent dexamethasone doses for both study arms. Administration of dexamethasone in the manner delineated by the elotuzumab product label adds complexity to the delivery of care. This commentary provides an empirical assessment of established medication safety and effectiveness which supports administration of dexamethasone standard intermittent dose instead of the split dose approach delineated on elotuzumab package insert. Simplification of regimen administration improves medication adherence, reduces the risk of inadvertent omission or duplication of medication therapy, and improves the workflow required for delivery of care.<\/jats:p>","DOI":"10.1177\/10781552231207855","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T03:04:25Z","timestamp":1698203065000},"page":"235-238","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Elotuzumab: Empiric analysis of dexamethasone administration schedule"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-4364","authenticated-orcid":false,"given":"Polly E","family":"Kintzel","sequence":"first","affiliation":[{"name":"Corewell Health West Michigan, Grand Rapids, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"bibr1-10781552231207855","unstructured":"Empliciti \u2013 (elotuzumab) for injection, for intravenous use. Prescribing information (accessed 22 March 2022)."},{"key":"bibr2-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12532"},{"key":"bibr3-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"bibr4-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"bibr5-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7618"},{"key":"bibr6-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-59403-9_31"},{"key":"bibr7-10781552231207855","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-1-8"},{"key":"bibr8-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.4.887.887"},{"key":"bibr9-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"bibr10-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"bibr11-10781552231207855","unstructured":"Center for Drug Evaluation and Research. Food and Drug Administration. Biologics License Application 761035Orig1s000. Elotuzumab (Emplicit). Medical\/ Statistical Review(s), www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/761035Orig1s000MedR.pdf (accessed 12 September 2023)."},{"key":"bibr12-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"bibr13-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.05.007"},{"key":"bibr14-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"bibr15-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"bibr16-10781552231207855","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544010-00003"},{"key":"bibr17-10781552231207855","unstructured":"Center for Drug Evaluation and Research. Food and Drug Administration. FDA\u2019s Drug Approval Process, www.fda.gov\/drugs\/information-consumers-and-patients-drugs\/fdas-drug-review-process-continued#quality (accessed 23 September 2023)."},{"key":"bibr18-10781552231207855","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302195"},{"key":"bibr19-10781552231207855","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4616"},{"key":"bibr20-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124156"},{"key":"bibr21-10781552231207855","unstructured":"Cancer Therapy Evaluation Program. Division of Cancer Treatment & Diagnosis. National Cancer Institute. Adverse Events\/CTCAE, https:\/\/ctep.cancer.gov\/protocolDevelopment\/adverse_effects.htm (accessed 24 September 2023)."},{"key":"bibr22-10781552231207855","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2001.n.005"},{"key":"bibr23-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1177\/0300060517713531"},{"key":"bibr24-10781552231207855","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231168594"},{"key":"bibr25-10781552231207855","unstructured":"Hodgens A, Sharman T. Corticosteroids. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554612\/ (accessed 24 September 2023)."},{"key":"bibr26-10781552231207855","unstructured":"National Library of Medicine. National Institutes of Health. Label: dexamethasone-dexamethasone tablet; dexamethasone solution, concentrate; dexamethasone solution, www.dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a (accessed 24 September 2023)."},{"key":"bibr27-10781552231207855","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines Version 1.2024. Multiple Myeloma, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf (accessed 24 September 2023)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231207855","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231207855","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231207855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:08Z","timestamp":1777688948000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231207855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1177\/10781552231207855"],"URL":"https:\/\/doi.org\/10.1177\/10781552231207855","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]}}}